150 results on '"Filippelli, Gianfranco"'
Search Results
2. Safety and Tolerability of Antimicrobial Agents in the Older Patient
3. GPER deletion triggers inhibitory effects in triple negative breast cancer (TNBC) cells through the JNK/c-Jun/p53/Noxa transduction pathway
4. The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells
5. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
6. Occupation, Literacy, Anthropometric Traits, and Life Expectancy of Italian Men Born 1900–1910: Evidence From Military Conscription Registers.
7. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?
8. Essential Oils from Southern Italian Aromatic Plants Synergize with Antibiotics against Escherichia coli , Pseudomonas aeruginosa and Enterococcus faecalis Cell Growth and Biofilm Formation.
9. Occupation, Literacy, Anthropometric Traits, and Life Expectancy of Italian Men Born 1900–1910: Evidence From Military Conscription Registers
10. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
11. Effectiveness of CAR-T treatment toward the potential risk of second malignancies.
12. Acalabrutinib in chronic lymphocytic leukemia
13. Myelodysplastic syndromes with ring sideroblasts
14. Iron chelation therapy
15. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
16. Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period
17. Elotuzumab in multiple myeloma
18. The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells
19. Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study
20. Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metastatic Colorectal Cancer: The Southern Italy Cooperative Oncology Group Experience
21. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: A randomized phase II SICOG trial
22. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology
23. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401
24. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
25. The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase I–II Study
26. Elotuzumab in multiple myeloma
27. Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period.
28. Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and Intravenous Bolus 5-Fluorouracil for Metastatic Colorectal Cancer: Pooled Analysis of Two Consecutive Southern Italy Cooperative Oncology Group Trials
29. A RANDOMIZED PHASE IIB STUDY OF WEEKLY PACLITAXEL (PCT) ± TRASTUZUMAB (T) AS FIRST-LINE THERAPY OF PATIENTS (PTS) WITH HER–2/NEU POSITIVE METASTATIC BREAST CANCER (MBC): RESULTS OF THE FIRST INTERIM ANALYSIS
30. Oxaliplatin plus folinic acid/fluorouracil i.v. bolus (OXAFAFU) vs irinotecan plus folinic acid/fluorouracil i.v. bolus (IRIFAFU) as first-line treatment of advanced colorectal carcinoma (ACC): Southern Italy Cooperative Oncology Group trial 0103
31. OXALIPLATIN PLUS LEUCOVORIN/FLUOROURACIL I.V. BOLUS (OXAFAFU) VERSUS IRINOTECAN PLUS LEUCOVORIN/FLUOROURACIL I.V. BOLUS (IRIFAFU) AS FIRST-LINE TREATMENT OF ADVANCED COLORECTAL CARCINOMA (ACC): SICOG 0103 RANDOMISED STUDY: 645
32. FLUOROURACIL (FU) PLUS FOLINIC ACID (FA) WITH IRINOTECAN (CPT-11) OR OXALIPLATIN (OHP) IN ADVANCED COLORECTAL CANCER (ACC) PATIENTS: PRELIMINARY SAFETY RESULTS OF A RANDOMIZED PHASE III MULTICENTER TRIAL OF THE GRUPPO ONCOLOGICO ITALIA MERIDIONALE (GOIM): 652
33. FOLFOX 4 AS FIRST LINE CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER (ACC). A PHASE II STUDY
34. Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
35. A PHASE I - II STUDY OF GEMCITABINE AND VINORELBINE AS SECOND LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER.
36. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
37. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
38. 5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology group
39. Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer
40. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
41. Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial—A SICOG (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts).
42. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study
43. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
44. Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.
45. Tumour‐associated macrophages correlate with microvascular bed extension in colorectal cancer patients
46. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond
47. Sorafenib: 10 years after the first pivotal trial
48. Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
49. Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey
50. Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.